1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,950 | 7,200 | 13:05 | |
| 7,050 | 7,100 | 22.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE ... | - | HKEx | ||
| Di | LEADS BIOLABS-B LBL-024 Clinical Study for Extrapulmonary Neuroendocrine Carcinoma Approved in Mainland China | 1 | AASTOCKS | ||
| Di | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY ... | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 15.05. | LEADS BIOLABS-B (09887): POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 14.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY | 2 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 08.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION AND PROPOSED IMPLEMENTATION OF H SHARE ... | - | HKEx | ||
| 06.05. | LEADS BIOLABS CO., LTD.: LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis | 1 | GlobeNewswire (USA) | ||
| 06.05. | LEADS BIOLABS-B Partner Dianthus Selects Three Priority Indications for LBL-047, Including Sjogren's Syndrome and Lupus | 3 | AASTOCKS | ||
| 06.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 PRIORITIZED FOR CLINICAL DEVELOPMENT IN SJOGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND ... | 1 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026 | - | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION ... | 2 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): 2025 ANNUAL REPORT | 2 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.04. | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase - Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies | 1 | GlobeNewswire (USA) | ||
| 21.04. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN PHASE II TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) ... | 1 | HKEx | ||
| 09.04. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results | 140 | GlobeNewswire (Europe) | NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,620 | 0,00 % | This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday | ||
| CG ONCOLOGY | 64,25 | 0,00 % | Wolfe Research startet Coverage für CG Oncology mit "Peerperform" | ||
| QIAGEN | 30,290 | +0,65 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,240 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,26 | -0,09 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,640 | -0,09 % | Cogent Biosciences: Aktie legt vor wichtigen Studiendaten um 4 % zu | ||
| GEOVAX LABS | 3,630 | -0,27 % | EQS-News: GeoVax, Inc.: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms 20.05.2026 / 16:06... ► Artikel lesen | |
| METAVIA | 3,850 | 0,00 % | MetaVia: Präklinische Studie zu Vanoglipel untermauert Potenzial bei Lebererkrankungen | ||
| IMMUNEERING | 5,390 | 0,00 % | Immuneering Corporation: Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | - Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,535 | +0,04 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| IMMUNOVANT | 34,140 | -0,03 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,640 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| INHIBRX BIOSCIENCES | 101,45 | +0,13 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,005 | -0,17 % | Morgan Stanley Raises its Price Target on Recursion (RXRX) |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,26 % bei einem Aktienkurs von 6,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.